-

Tempus Introduces AI-enabled Assistant, Tempus One, Into Lens Data Analytics Platform to Accelerate Research

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced the integration of its signature Tempus One technology into its Lens data analytics platform. The AI-enabled Tempus One technology will leverage advancements in generative AI to provide researchers the tools they need to seamlessly analyze Tempus’ de-identified, multimodal data library to glean insights, build patient cohorts, interrogate patient populations, and more.

Tempus One was broadly released to physicians at the 2023 ASCO® Annual Meeting, designed as an AI-enabled clinical assistant that allows rapid and easy queries through voice or typing, leveraging access to their patients’ full clinical and molecular profile, combined with all relevant guidelines for up-to-date standard of care insights. Now, this generative AI technology is being introduced to Tempus’ research collaborators within the Tempus Lens platform, to more seamlessly identify and analyze cohorts of interest, to quickly answer questions and develop deeper insights.

The integration of Tempus One into Lens will begin with the inclusion of user Q&A through an in-app chat assistant powered by large language models (LLMs) across the Lens platform, which will make the vast amounts of data more accessible for researchers through the enhanced support function. Users will be able to send questions directly to the chat, receive real time answers including citations and links to additional information, and provide feedback on chat response quality. The integration will also include a cohort building technology facilitated by LLMs, allowing users to more quickly size and find patient cohorts across a hundred clinical and molecular attributes within Tempus’ dataset.

“We are looking forward to expanding our Tempus One technology to our life sciences collaborators,” said Ryan Fukushima, Chief Operating Officer of Tempus. “The incorporation of our generative AI capabilities into Lens will improve the functionality of the platform for users, so they can more easily leverage our data and insights at their fingertips.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Erin Carron
Senior Director of Communications
communications@tempus.com

Tempus


Release Versions

Contacts

Erin Carron
Senior Director of Communications
communications@tempus.com

More News From Tempus

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is designed to transform care delivery across more than 1.5 million annual patient visits to the USC Norris Comprehensive Cancer Center, t...

Tempus to Report First Quarter 2026 Financial Results on May 5

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live...

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta™, intended for the comprehensive genomi...
Back to Newsroom